DVAX: Dynavax Technologies Corporation - Summary | Jitta

Dynavax Technologies Corporation

NASDAQ:DVAX

Price
$12.30
Loss Chance
44.5%
3.95JITTA SCORE
72.71%Under Jitta Line
Jitta Ranking
9 / 1,197
290 / 5,063
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (74)
Recent Business Performance (79)
Financial Strength (51)
Return to Shareholders (22)
Competitive Advantage (61)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning loss detected in 2020
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
3.95
72.71%
1.31
114.85%
2.00
236.83%
Biotechnology
6.10
57.92%
5.54
31.25%
4.87
7.96%
COMPANY DESCRIPTION
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.